Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322729 | 0.85 | KCNA3 (0.40) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL4319367 | 0.82 | ATM (0.52) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL4334115 | 0.72 | OPRL1 (0.48) | NPSR1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL6746046 | 0.72 | KDM4E (0.60) | KCNA3KDM4ENPSR1OPRM1OPRD1 | |
| SCHEMBL4341092 | 0.71 | OPRL1 (0.41) | OPRM1OPRD1OPRK1ADRA1AOPRL1 | |
| SCHEMBL11282136 | 0.70 | OPRM1 (0.80) | KCNA3KDM4ENPSR1OPRM1OPRD1 | |
| SCHEMBL4341190 | 0.70 | OPRL1 (0.43) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4330985 | 0.70 | SMN1; SMN2 (0.44) | OPRM1OPRD1OPRK1SLC6A4OPRL1 | |
| SCHEMBL2789658 | 0.69 | KDM4E (0.61) | KCNA3KDM4ENPSR1OPRM1OPRD1 | |
| SCHEMBL5330651 | 0.68 | CYP2D6 (0.61) | KCNA3KDM4ENPSR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | KCNA3 403/4885KDM4E 3662/4885NPSR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.